KPTI, US48576U2050

Karyopharm schedules November 2 results for Karyopharm stock

Published on 10/27/2026 at 22:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 revenue consensus is USD 33.54 million versus USD 33.43 million in Q2. Karyopharm stock costs EUR 0.41 on October 27, 2026 at 10:52 p.m. CEST.

Reporting date and revenue

The next Karyopharm report is scheduled for November 2, 2026, before market open.
Second-quarter revenue was USD 33.43 million versus USD 37.90 million a year earlier.
Karyopharm stock costs EUR 0.41 at Lang & Schwarz on October 27, 2026 at 10:52 p.m. CEST.

KPTI, US48576U2050, Illustration mit AI erstellt.

Karyopharm Therapeutics (US48576U2050) is estimated to report its third-quarter 2026 results on November 2, 2026, before market open, according to MarketBeat. The company stock costs EUR 0.41 at Lang & Schwarz on October 27, 2026 at 10:52 p.m. CEST.

Revenue remains below last year

Karyopharm reported USD 33.43 million in revenue for the second quarter of 2026, down from USD 37.90 million in the second quarter of 2025. Business Quant lists the quarter at USD 33.43 million against a USD 30.27 million consensus estimate, a 10.44 percent beat.

Price position stays wide

The stock's 52-week range is USD 0.31 to USD 10.99, while market capitalization is USD 10.9 million and volume reached 986,007 shares on October 27, 2026. The wide range underlines how sharply the valuation has moved across the past year, although the euro quotation remains below EUR 1.00.

What matters before November 2?

MarketBeat lists a Q3 2026 consensus of USD 33.54 million in revenue and negative USD 1.16 adjusted earnings per share. The same source compares that with USD 44.04 million of revenue and negative USD 3.82 earnings per share in the year-earlier quarter. The figures make the November report a test of whether quarterly revenue can stabilize near the USD 33 million level.

Company keeps oncology focus

Karyopharm describes itself as a commercial-stage pharmaceutical company focused on cancer therapies. Its lead medicine, selinexor, is marketed as XPOVIO in the United States and NEXPOVIO in some international markets, according to the company's Karyopharm investor-relations profile.

Trading snapshot

The stock was trading at EUR 0.41 at Lang & Schwarz on October 27, 2026 at 10:52 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Karyopharm Therapeutics stock.